Social Media Posts About Cancer: Five Timepoints

by palligoelme@gmail.com | May 15, 2026 | Clinical Trials

​ Conditions: Cancer Interventions: Behavioral: Social cue prompt and policy; Behavioral: Standard prompts Sponsors: UNC Lineberger Comprehensive Cancer Center Completed Conditions: Cancer Interventions: Behavioral: Social cue prompt and policy; Behavioral: Standard...

Epcoritamab in Combination With R-CHOP for Patients With Aggressive Non-Hodgkin Lymphoma

by palligoelme@gmail.com | May 15, 2026 | Clinical Trials

​ Conditions: Non-Hodgkin’s B-cell Lymphoma; Lymphoma Non-Hodgkin; Diffuse Large B-Cell Lymphoma (DLBCL) Interventions: Drug: Rituximab, Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisolone (R-CHOP); Drug: Epcoritamab; Drug: Dexamethasone; Procedure:...

Effect of Integrated Neuromuscular Inhibition Technique on Hand Grip Strength in Upper Trapezius Myofascial Trigger Points

by palligoelme@gmail.com | May 15, 2026 | Clinical Trials

​ Conditions: Myofascial Trigger Point Pain Interventions: Other: Integrated Neuromuscular Inhibition Technique; Other: Conventional Physical Therapy Sponsors: Cairo University Not yet recruiting Conditions: Myofascial Trigger Point Pain Interventions: Other:...

Intertransverse Process Block Versus Subcostal Transversus Abdominis Plane Block After Laparoscopic Sleeve Gastrectomy

by palligoelme@gmail.com | May 15, 2026 | Clinical Trials

​ Conditions: Intertransverse Process Block; Subcostal Transverse Abdominis Plane Block; Sleeve Gastrectomy; Postoperative Pain; Regional Anaesthesia Interventions: Procedure: Intertransverse Process Block; Procedure: The Subcostal Transversus Abdominis Plane Block...

A Study to Evaluate Dermal Open-Flow Microperfusion and Plasma Pharmacokinetic Study of Multiple Doses of Oral Povorcitinib or Topical Ruxolitinib Cream in Healthy Adult Participants

by palligoelme@gmail.com | May 14, 2026 | Clinical Trials

​ Conditions: Healthy Participants Interventions: Drug: Povorcitinib; Drug: Ruxolitinib Sponsors: Incyte Corporation Recruiting Conditions: Healthy Participants Interventions: Drug: Povorcitinib; Drug: Ruxolitinib Sponsors: Incyte Corporation...